ReviewThe Journal of infectious diseases2020
Advances in the Development of Therapeutics for Cytomegalovirus Infections.
Review in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Concomitant Hemophagocytic Lymphohistiocytosis and Cytomegalovirus Disease: A Case Based Systemic Review.Frontiers in medicine · 2022Pooled it
- Limited protection against early-life lung murine cytomegalovirus infection results from deficiency of cytotoxic CD8 T cells.PLoS pathogens · 2026Article
- Cytomegalovirus in HIV: A Modifiable Driver of Inflammation, Frailty, and Aging.Current HIV/AIDS reports · 2026Review
- Transverse Comparison of Clinical Characteristics and Prognostic Factors in HIV-Infected Patients with Cytomegalovirus Encephalitis in Guangdong, China.Current HIV research · 2026Article
- Review
- Antiviral treatment for viral pneumonia: current drugs and natural compounds.Virology journal · 2025Review
- Auditory and Vestibular Involvement in Congenital Cytomegalovirus Infection.Pathogens (Basel, Switzerland) · 2024Review
- The ATP-Binding Cassette Transporter-Mediated Efflux Transport of Ganciclovir at the Blood-Brain Barrier.European journal of drug metabolism and pharmacokinetics · 2024Article
- 'Getting Better'-Is It a Feasible Strategy of Broad Pan-Antiherpesviral Drug Targeting by Using the Nuclear Egress-Directed Mechanism?International journal of molecular sciences · 2024Review
- Human Cytomegalovirus (HCMV) Genetic Diversity, Drug Resistance Testing and Prevalence of the Resistance Mutations: A Literature Review.Tropical medicine and infectious disease · 2024Review
- Navigating paediatric virology through the COVID‑19 era (Review).International journal of molecular medicine · 2023Review
- A seromolecular study to determine the prevalence of cytomegalovirus in pregnant women referred to health centers in the north of Iran.Iranian journal of microbiology · 2023Article
- Secondary haemophagocytic lymphohistiocytosis in a patient with new-onset systemic lupus erythematosus: the challenges of timely diagnosis and successful treatment.BMJ case reports · 2023Article
- The hard part we often forget: providing care to children and adolescents with advanced HIV disease.Journal of the International AIDS Society · 2023Article
- Correlation of cytomegalovirus viral load between whole blood and plasma of congenital cytomegalovirus infection under valganciclovir treatment.BMC infectious diseases · 2023Article
- Antiviral Drugs in Adenovirus-Induced Keratoconjunctivitis.Microorganisms · 2022Review
- An Overview of Cytomegalovirus Infection in Pregnancy.Diagnostics (Basel, Switzerland) · 2022Review
- Pulmonary tuberculosis infection and CMV reactivation following daratumumab treatment in a patient with relapsed plasmablastic lymphoma.Blood science (Baltimore, Md.) · 2022Article
- Cyclin-Dependent Kinases (CDKs) and the Human Cytomegalovirus-Encoded CDK Ortholog pUL97 Represent Highly Attractive Targets for Synergistic Drug Combinations.International journal of molecular sciences · 2022Article
- Prevention and management of human cytomegalovirus in pediatric HSCT recipients: A review.Frontiers in pediatrics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
The development of therapeutics for cytomegalovirus (CMV) infections, while progressing, has not matched the pace of new treatments of human immunodeficiency virus (HIV) infections; nevertheless, recent developments in the treatment of CMV infections have resulted in improved human health and perhaps will encourage the development of new therapeutic approaches. First, the deployment of ganciclovir and valganciclovir for both the prevention and treatment of CMV infections and disease in transplant recipients has been further improved with the licensure of the efficacious and less toxic letermovir. Regardless, late-onset CMV disease, specifically pneumonia, remains problematic. Second, the treatment of congenital CMV infections with valganciclovir has beneficially improved both hearing and neurologic outcomes, both fundamental advances for these children. In these pediatric studies, viral load was decreased but not eliminated. Thus, an important lesson learned from studies in both populations is the need for new antiviral agents and the necessity for combination therapies as has been shown to be beneficial in the treatment of HIV infections, among others. The development of monoclonal antibodies, sirtuins, and cyclopropovir may provide new treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.